Please use this identifier to cite or link to this item: http://repository.i3l.ac.id/jspui/handle/123456789/787
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTania, Sandra-
dc.date.accessioned2023-05-30T07:24:44Z-
dc.date.available2023-05-30T07:24:44Z-
dc.date.issued2021-06-01-
dc.identifier.urihttp://repository.i3l.ac.id/jspui/handle/123456789/787-
dc.description.abstractThe current first-line drugs for NSCLC with EGFR mutation as the driver oncogene are tyrosine kinase inhibitor (TKI) which act specifically on blocking the mutated EGFR protein to stop the signal transduction and therefore inhibit the proliferation of the cancer. However, all patients are eventually developing acquired resistance to the first line of TKI therapies mostly after 6-12 months of treatment initiation and afterwards the resistance also occurs on the second line and later throughout the remedy. PD-1/PD-L1 blocker might be useful to be the alternative treatment. NSCLC patients with EGFR mutation subtype L858R mutation had the better overall response rate and overall survival after treatment with PD-1/PD-L1 blocker, compared those with subtype exon 19 deletion. To understand the mechanism which lies behind the better outcomes of the subtype L858R, this study measured the PD-L1 DNA copy number and mRNA expression of EGFR-mutated NSCLC cell lines with L858R mutation (H1975), exon 19 deletion (H1650), and control wild-type EGFR (A549). These cells were cultured and treated with IFN-γ (30 minutes, 6 hours, and 24 hours of induction). The quantification of the PD-L1 transcription level (RNA) and the DNA copy number were done with quantitative Polymerase Chain Reaction (qPCR). The experiment also compared the expression with and without IFN-γ exposure. The result is that H1975 cell line had PD-L1 DNA copy number reduction and that the better outcomes did not related to H1975 induced expression. The L858R subtype superior result might be related to tumor infiltrating lymphocyte existence and tumor mutation burden of the cancer.en_US
dc.language.isoenen_US
dc.publisherIndonesia International Institute for Life Sciencesen_US
dc.relation.ispartofseriesT202012027;T202012027-
dc.subjectNSCLC cell linesen_US
dc.subjectPD-1/PD-L1 Blockeren_US
dc.subjectEGFR subtypesen_US
dc.subjectIFN-γen_US
dc.subjectqPCRen_US
dc.titleThe Comparison of PD-L1 DNA Copy Number and Relative MRNA Expression Between EGFR Mutation Subtypes of NSCLC Cell Linesen_US
dc.typeThesisen_US
Appears in Collections:Biomedicine

Files in This Item:
File Description SizeFormat 
Chapter 1.pdfChapter 11.29 MBAdobe PDFView/Open
cover.pdfCover1.29 MBAdobe PDFView/Open
References.pdfReferences1.29 MBAdobe PDFView/Open
T202012027_Sandra Tania.pdf
  Restricted Access
Full Text1.3 MBAdobe PDFView/Open Request a copy
Abstract.pdfAbstract1.29 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.